• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    11/14/24 6:17:23 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    SC 13G/A 1 zk2432318.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549

    SCHEDULE 13G
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)*

    Sol-Gel Technologies Ltd.
    (Name of Issuer)

    Ordinary Shares, par value NIS 0.1 per share
     (Title of Class of Securities)

    M8694L103
     (CUSIP Number)

    September 30, 2024
     (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. M8694L103
    13G
    Page 2 of 8 Pages
     
    1
    NAMES OF REPORTING PERSONS
     
     
     
    Phoenix Financial Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See instructions)
       
    (a) ☐
       
    (b) ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Israel
     
     
     
     
    NUMBER OF
    SHARES BENEFICIALLY OWNED BY
    EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
     
     
    ---
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     
    2,470,192  (*)
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    ---
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    2,470,192  (*)
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    2,470,192  (*)
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See instructions)
     
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     
    8.87% (*)(**)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (See instructions)
     
     
     
    CO
     
     
     
     
     
    (*) The beneficial ownership of the securities reported herein is described in Item 4(a).

    (**) Based on 27,857,620 Ordinary Shares outstanding as of October 15, 2024 (as reported on Bloomberg LP).

    2

    Item 1.        (a)         Name of Issuer:

             Sol-Gel Technologies Ltd.

                         (b)
    Address of Issuer's Principal Executive Offices:

     7 Golda Meir St., Ness Ziona 7403650, Israel

    Item 2.        (a)
    Name of Person Filing:

    Phoenix Financial Ltd.

    The securities reported herein are beneficially owned by various direct or indirect, majority or wholly-owned subsidiaries of Phoenix Financial Ltd. (the "Subsidiaries").  The Subsidiaries manage their own funds and/or the funds of others, including for holders of exchange-traded notes or various insurance policies, members of pension or provident funds, unit holders of mutual funds, and portfolio management clients. Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.


    (b)
    Address of Principal Business Office:

    The address of Phoenix Financial Ltd. is Derech Hashalom 53, Givataim, 53454, Israel. 


    (c)
    Citizenship:

    Phoenix Financial Ltd. - Israel


    (d)
    Title of Class of Securities:

    Ordinary Shares, par value NIS 0.1 per share


    (e)
    CUSIP Number:

    M8694L103

    Item 3.
    Not applicable.

    Item 4.
    Ownership:


    (a)
    Amount beneficially owned:

    See row 9 of cover page of each reporting person.

    Each of the Subsidiaries operates under independent management and makes its own independent voting and investment decisions.  Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by either the Filing Persons or Subsidiaries that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each reporting person disclaims the existence of any such group.  In addition, each of the Filing Persons and Subsidiaries disclaims any beneficial ownership of the securities covered by this report in excess of their actual pecuniary interest therein. This Statement shall not be construed as an admission by the Filing Persons or Subsidiaries that they are the beneficial owners of any of the Ordinary Shares covered by this Statement, and each of Filing Persons and Subsidiaries disclaims beneficial ownership of any such Ordinary Shares.
    3

    As of September 30, 2024, the securities reported herein were held as follows:

       
    Ordinary Shares
       
    Percentage of total Ordinary Shares outstanding
     
    The Phoenix Investments House - "nostro" accounts
       
    --
         
    --
     
    The Phoenix Investments House - trust funds
       
    --
         
    --
     
    The Phoenix Investments House - ETF's
       
    --
         
    --
     
    The Phoenix "nostro" accounts
       
    288,045
         
    1.03
    %
    The Phoenix pension
       
    --
         
    --
     
    The Phoenix pension and provident funds
       
    --
         
    --
     
    Partnership for Israeli shares (1)
       
    --
         
    --
     
    Partnership for investing in shares indexes (1)
       
    --
         
    --
     
    Partnership for international shares (1)
       
    2,182,147
         
    7.83
    %
    Halman - Aldubi Provident and Pension Funds Ltd.
       
    --
         
    --
     

    (1) All ownership rights in this partnership belong to companies that are part of Phoenix Group. The amount of ownership rights held by such companies in the partnership changes frequently according to a mechanism provided in the partnership agreement.


    (b)
    Percent of class:

    See row 11 of cover page of each reporting person


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote:

    See row 5 of cover page of each reporting person


    (ii)
    Shared power to vote or to direct the vote:

    See row 6 of cover page of each reporting person and note in Item 4(a) above


    (iii)
    Sole power to dispose or to direct the disposition of:

    See row 7 of cover page of each reporting person


    (iv)
    Shared power to dispose or to direct the disposition of:

    See row 8 of cover page of each reporting person and note in Item 4(a) above

    4




    Item 5.
    Ownership of Five Percent or Less of a Class:

    Not applicable.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another:

    Not applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

    Item 8.
    Identification and Classification of Members of the Group:

    Not applicable.

    Item 9.
    Notice of Dissolution of Group:

    Not applicable.

    5

     
    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    6


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    November 13, 2024
     
         
    Phoenix Financial Ltd.
     
    /s/ Eli Schwartz
    By: Eli Schwartz*
    Title: Executive Vice President - Chief Financial Officer

         
    /s/ Haggai Schreiber
    By: Haggai Schreiber*
    Title: Executive Vice President - Chief Investment Officer
     

    * Signature duly authorized by resolution of the Board of Directors, notice of which is attached as Exhibit 1 to this Schedule 13G.
    7

     
    EXHIBIT NO.          DESCRIPTION
     
    Exhibit 1
    Notice of resolution of the Board of Directors of Phoenix Financial Ltd., dated as of December 12, 2019 (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on February 7, 2022).

     8

     
    Get the next $SLGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sol-Gel Announces Reverse Share Split

      NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL), a clinical-stage dermatology company, today announced a reverse share split (the "Reverse Split") of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the "Ordinary Shares"), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders' approval for the Reverse Split at a ratio of between 2:1 and 10:1 at a special meeting of shareholders, which took place on April 1, 2025. The Company's board of directors then approved the Reverse Split ratio of 10-for-1 on Ap

      5/1/25 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

      Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL

      4/17/25 8:40:29 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

      NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC's ("Nasdaq") minimum bid price rule. On November 19, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has d

      11/20/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sol-Gel downgraded by Raymond James with a new price target

      Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

      8/19/24 6:57:49 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Sol-Gel with a new price target

      Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

      10/21/22 7:42:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

      HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

      11/15/21 1:18:47 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

      Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

      7/27/21 10:39:03 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Sol-Gel Technologies Ltd.

      EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/9/25 12:15:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Sol-Gel Technologies Ltd.

      424B3 - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/8/25 10:24:35 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by Sol-Gel Technologies Ltd.

      6-K/A - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/8/25 9:38:47 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

      SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      11/14/24 4:37:49 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

      SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      11/14/24 6:17:23 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sol-Gel Technologies Ltd. (Amendment)

      SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      4/8/24 9:28:09 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Financials

    Live finance-specific insights

    See more
    • Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

      An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

      3/13/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

      5/12/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

      Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

      3/10/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

      Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September

      11/15/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu

      11/10/22 4:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

      NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,

      10/3/22 8:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care